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2q23.1 deletion syndrome is characterized by intellectual disability, speech impairment, seizures, disturbed sleep
pattern, behavioral problems, and hypotonia. Core features of this syndrome are due to haploinsufficiency of MBD5.
Deletions that include coding and noncoding exons show reduced MBD5 mRNA expression. We report a patient
with a neurological and behavioral phenotype similar to 2q23.1 deletion syndrome with an inherited intronic
deletion in the 5-prime untranslated region of MBD5. Our data show that this patient has normal MBD5 mRNA
expression; therefore, this deletion is likely not causative for 2q23.1 deletion syndrome. Overall, it is important to
validate intronic deletions for pathogenicity.
Keywords: 2q23.1 deletion syndrome, MBD5, 5′UTR, Intronic deletion, Gene expression, Familial variantThe 2q23.1 microdeletion syndrome (OMIM 156200) is a
neurodevelopmental disorder characterized by intellectual
disability, severe speech impairment, seizures, disturbed
sleep pattern, behavioral problems, microcephaly, hypo-
tonia and short stature [1,2] and is caused by deletions of
chromosome 2 involving the 2q23.1 band or mutation in
the methyl-CpG binding protein 5 gene, MBD5 (OMIM
611472) [2]. MBD5 belongs to the MBD family of pro-
teins, which play critical roles in transcriptional regulation
and development. The gene structure contains five non-
coding exons at the 5-prime end, followed by 10 coding
exons (Figure 1). Two protein isoforms have been de-
scribed [3]. The first isoform contains 1494 amino acids
and is encoded by exons 6–15 (Figure 1). The second iso-
form is shorter, contains 851 amino acids, and is encoded
by exons 6–9. Talkowski et al. [2] showed that deletions
that include noncoding exons, which do not alter the
MBD5 protein coding sequence, show reduced MBD5
mRNA expression, similar to that observed in individuals
with larger 2q23.1 microdeletions encompassing the entire
MBD5 gene. The individuals with these MBD5 non-coding
exonic deletions exhibit most features of 2q23.1 microdele-
tion syndrome [2].
In this study, a 4-year-old boy (SMS431) was referred
for a possible diagnosis of 2q23.1 deletion syndrome* Correspondence: elsea@bcm.edu
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article, unless otherwise stated.based upon array CGH findings using Nimblegen CGX-
12 (Roche Technologies, Penzberg, Germany). The DNA
microarray analysis of SMS431, his clinically normal par-
ents, and paternal grandparents was performed in a clin-
ical laboratory, revealing a 0.061 Mb paternally inherited
deletion at 2q23.1, arr [hg19] 2q23.1 (149,036,875-
149,098,081)x1. This region involves a portion of intron
4 of MBD5 (Figure 1). This deletion also was found to
be present in the paternal grandfather (Figure 2).
While the neurological and behavioral phenotype of
SMS431 was remarkably similar to 2q23.1 deletion
phenotype (Table 1), it was unclear whether such an in-
tronic deletion in the noncoding region of the MBD5
gene could be deleterious and manifest the phenotypes
present in this child. Additionally, both father and pater-
nal grandfather carry this deletion and neither have fea-
tures associated with 2q23.1 deletion syndrome or other
features observed in this child. Reduced MBD5 mRNA
expression has been reported in 2q23.1 deletion patients
and serves as an additional molecular diagnostic indica-
tor for this disorder [2,4]. Consequently, to determine
whether a deletion in the noncoding intron 4 region of
MBD5 could result in impaired expression of MBD5 and
was, therefore, responsible for the phenotype observed
in SMS431, we evaluated MBD5 mRNA gene expression
on peripheral blood samples obtained from this family.
The Institutional Review Board Baylor College of
Medicine approved this study. Fresh blood was collectedCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Intragenic deletion involving a portion of MBD5 intron 4. A schematic representation of MBD5, depicting the 5′-UTR, exons (black
boxes), and intronic regions. We depict the .061 Mb intron 4 deletion (in red) in the 5′-noncoding region of MBD5 at chr(2)(q23.1); (chr2.hg19:g.
149,036,875-149,098,081).
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(mother), SMS361 (2q23.1 deletion patient) [5], and nine
normal controls after informed consent was obtained.
Total RNA was isolated according to standard methods
(Invitrogen, Carlsbad, CA). RNA was quantified using
the NanoDrop ® ND-100 Spectrophotometer and reverse
transcribed through qSCRIPT cDNA SuperMix (Quanta
Biosciences, Inc., Gaithersburg, MD) according to manu-
facturer’s instructions. To assess MBD5 mRNA expres-
sion, quantitative RT-PCR was performed as previously
described [2,6]. Briefly, Taqman minor groove binder
probes for MBD5 (OMIM 611472, Hs00289233_m1)
and GAPDH (OMIM 138400, Hs9999905_m1) were
used. GAPDH was used as the endogenous control. AllFigure 2 Pedigree of a family with intron 4 deletion of MBD5. The pro
and circles symbolize males and females, respectively. The small light greysamples of cDNA were run in triplicate in 10 ul reaction
volumes. All samples were run and analyzed according
to previously published methods using BioRad CFX
Connect™ Real-Time PCR Detection System [2]. Three
biological replicates were performed. Results are expressed
as fold-change relative to the control sample. Standard
error was generated for each sample. A paired t-test was
used to determine significance. p <0.01 was considered
statistically significant.
As expected, MBD5 mRNA expression for the mother
was not statistically different from controls (P = 0.767)
(Figure 3), while the 2q23.1 deletion control sample,
SMS456, exhibited the typical reduced MBD5 mRNA
expression for an individual with an MBD5 deletionband (SMS431) is denoted by arrow and small black box. The squares
boxes denote family members carrying the MBD5 intron 4 deletion.
Table 1 Comparison of the phenotype of SMS431 to the
prominent features of 2q23.1 deletion syndrome







Repetitive behaviors (stereotypies) +
Self-injurious behaviors +




Infantile feeding difficulties +
Eye abnormalities +
Heavy arched eyebrows -
Prominent nose -
Thin upper lip +
Widely spaced teeth -
*Intronic deletion of intron 4 in the 5′UTR region of MBD5.
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(SMS431) and his father (SMS432) were not significantly
different from controls (P = 0.060) (Figure 3) or from
MBD5 expression for the mother. Further, SMS431 and
SMS432 expression patterns were significantly different
from a typical 2q23.1 deletion case, SMS456 (P < 0.0001).
Since the deletion present in SMS431 and his father didFigure 3 MBD5 mRNA expression is not altered in individuals
with MBD5 intronic deletion. Quantitative RT-PCR was used to test
MBD5 mRNA expression levels. MBD5 mRNA expression levels are
not significantly altered in SMS431 (child) or SMS432 (father) or
SMS433 (mother) compared to controls. The expression of a typical
2q23.1 deletion syndrome case shows significantly reduced MBD5
expression compared to controls.not alter MBD5 mRNA expression, it is highly unlikely
that this intronic deletion affects transcription and transla-
tion of MBD5, and furthermore, no truncated mRNA,
truncated protein or aberrant protein should result.
A survey of the Database of Genomic Variants (DGV)
contains no deletions that are identical to that observed
in the individuals in this family. DVG lists 14 small dele-
tions in the 5′-noncoding region of MBD5, with nine
deletions confined to intronic sequences, which were re-
ported to be nonpathogenic or of unknown significance.
Five of the nine small deletions were found in intron 4.
Overall, it is apparent that the intron 4 deletion does
not affect expression of MBD5 and likely does not give
rise to the features associated with the MBD5 haploin-
sufficiency that is observed in 2q23.1 deletion syndrome.
Introns in the noncoding region of a gene can play a
major role in the transcriptional regulation of a gene
and consequently, gene expression. An intron can en-
hance gene expression through the presence of tran-
scriptional regulatory elements or through structural
modulation and splicing [7]. Copy number variants
within splice site sequences at the intron-exon junction
cause approximately 10% of disease-causing mutations
[8]. There are several cases in the medical literature of
pathogenic intronic deletions such as NRXN1 deletions
(Autism Spectrum Disorder) [9], SLC34A3 deletions (her-
editary hypophosphatemic rickets with hypercalciuria)
[10,11], PKD1 deletions (Rothmund-Thomson syndrome)
[12], and NASE deletions (5-fluorouracil toxicity) [13].
Since the intronic deletion identified in SMS431 does
not delete the splice junctions between exon 4 and exon
5 or create new splice junctions, proper mRNA splicing
likely still occurs, without impacting expression. Further,
deletions in 5-prime UTR introns could lead to altered
expression if transcription factor binding is affected.
Whether there are transcription factors, enhancers, or
silencers that bind to that specific intronic region of
MBD5 remains unclear.
In summary, SMS431 exhibited developmental delay,
motor delay, severe language impairment, sleep distur-
bances and behavioral problems that mimicked 2q23.1
deletion syndrome (Table 1). However, these neurological
and behavioral phenotypes are observed in other neurode-
velopmental disorders. The 2q23.1 deletion syndrome
phenotype overlaps with other neurodevelopmental disor-
ders, including Angelman syndrome, Smith-Magenis syn-
drome, Pitt-Hopkins syndrome, and Kleefstra syndrome
[2,6]. SMS431 likely has a different neurodevelopmental
disorder that overlaps phenotypically with 2q23.1 deletion
syndrome. Since no other copy number variants were iden-
tified for this patient, additional testing will be required to
determine a cause for the phenotype. The possibility exists
that a gene that is involved in a pathway common to
MBD5 may be affected, including a gene downstream of
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sequencing (WES) may be the best approach toward diag-
nosis for this child.
In conclusion, we highlight the importance of validat-
ing intronic deletions for pathogenicity so that accurate
and informed diagnosis can be provided to the patient.
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